ClassID:

109162

C12N2310/315 - page 3 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates

Recent Application in this class:
#601
20240293563
2024-09-05

GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF

#602
20240287566
2024-08-29

NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES

#603
20240287528
2024-08-29

TRANSGLUTAMINASE-MEDIATED CONJUGATION

#604
20240287526
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC OLIGONUCLEOTIDES TO THE CENTRAL NERVOUS SYSTEM

#605
20240287524
2024-08-29

GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#606
20240287523
2024-08-29

TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

#607
20240287519
2024-08-29

TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS

#608
20240287518
2024-08-29

TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS

#609
20240287517
2024-08-29

TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS

#610
20240287515
2024-08-29

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)

#611
20240287514
2024-08-29

OLIGONUCLEOTIDES FOR IFN-GAMMA SIGNALING PATHWAY MODULATION

#612
20240287513
2024-08-29

Compounds and Methods for Modulating Splicing of Pre-MRNA

#613
20240287512
2024-08-29

LIPID CONJUGATION FOR TARGETING NEURONS OF THE CENTRAL NERVOUS SYSTEM

#614
20240287510
2024-08-29

OLIGONUCLEOTIDES

#615
20240285669
2024-08-29

Compounds and Methods for Modulating GFAP

#616
20240279664
2024-08-22

Conjugated antisense compounds and their use

#617
20240279663
2024-08-22

TREATMENT OF ANGPTL4 RELATED DISEASES

#618
20240279658
2024-08-22

DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO

#619
20240279655
2024-08-22

LIGAND-BINDING NUCLEIC ACID COMPLEX

#620
20240279654
2024-08-22

COMPOUNDS FOR REDUCING PTBP1 EXPRESSION

#621
20240279653
2024-08-22

FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF

#622
20240279652
2024-08-22

RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES

#623
20240271144
2024-08-15

SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#624
20240271143
2024-08-15

POLYNUCLEIC ACID MOLECULES TARGETING PCSK9 AND USES THEREOF

#625
20240271141
2024-08-15

COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF HEPATITIS B VIRUS (HBV)PROTEIN

#626
20240271136
2024-08-15

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#627
20240271132
2024-08-15

MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION

#628
20240271130
2024-08-15

LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES

#629
20240263179
2024-08-08

METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY

#630
20240263177
2024-08-08

Methods and Compositions for Adar-Mediated Editing

#631
20240254493
2024-08-01

COMPOSITIONS AND METHODS FOR SILENCING CARBONIC ANHYDRASE 2 EXPRESSION

#632
20240254491
2024-08-01

BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#633
20240254490
2024-08-01

Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof

#634
20240254487
2024-08-01

MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#635
20240254486
2024-08-01

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#636
20240254484
2024-08-01

SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#637
20240254482
2024-08-01

METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

#638
20240247272
2024-07-25

ANTISENSE OLIGONUCLEOTIDE TARGETING CAV3.1 GENE AND USES THEREOF

#639
20240247271
2024-07-25

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

#640
20240247268
2024-07-25

Modulators of Complement Factor B

#641
20240247266
2024-07-25

METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER

#642
20240247263
2024-07-25

METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY

#643
20240247260
2024-07-25

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

#644
20240245784
2024-07-25

TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS

#645
20240240188
2024-07-18

ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE

#646
20240240187
2024-07-18

SIRNA TARGETING TMPRSS6 FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS

#647
20240240186
2024-07-18

COMB SHAPED ANTIVIRALS ENDING WITH OR WITHOUT CHAIN TERMINATING BASES

#648
20240240182
2024-07-18

HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#649
20240240170
2024-07-18

POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS

#650
20240238394
2024-07-18

COMPOSITIONS, SYSTEMS AND METHODS OF RNA EDITING USING DKC1

#651
20240238344
2024-07-18

COMPOSITIONS AND METHODS FOR CD123 MODIFICATION

#652
20240229042
2024-07-11

COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION

#653
20240229037
2024-07-11

SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE

#654
20240229030
2024-07-11

NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION

#655
20240229029
2024-07-11

COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA

#656
20240229028
2024-07-11

SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE

#657
20240229026
2024-07-11

CHIRAL CONTROL

#658
20240229025
2024-07-11

siRNA AND USE THEREOF

#659
20240229011
2024-07-11

MODIFIED NUCLEIC ACIDS, HYBRID GUIDE RNAS, AND USES THEREOF

#660
20240229010
2024-07-11

TUNING CRISPR/CAS9 ACTIVITY WITH CHEMICALLY MODIFIED NUCLEOTIDE SUBSTITUTIONS

#661
20240228577
2024-07-11

Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy

#662
20240226339
2024-07-11

Materials and Methods for Treatment of Hemoglobinopathies

#663
20240226334
2024-07-11

CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR

#664
20240218428
2024-07-04

COMPOSITIONS OF MATTER FOR DETECTION ASSAYS

#665
20240218361
2024-07-04

MODULATING APOLIPOPROTEIN (A) EXPRESSION

#666
20240218354
2024-07-04

GUIDE RNAS WITH CHEMICAL MODIFICATION FOR PRIME EDITING

#667
20240216522
2024-07-04

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA

#668
20240216359
2024-07-04

TREATMENT OF NEUROLOGICAL DISORDERS

#669
20240209377
2024-06-27

THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS

#670
20240209376
2024-06-27

Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons

#671
20240209374
2024-06-27

iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN

#672
20240209373
2024-06-27

ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#673
20240209372
2024-06-27

PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#674
20240209371
2024-06-27

COMPOSITIONS AND METHODS FOR TREATING CANCER

#675
20240209369
2024-06-27

Complement component C3 iRNA compositions and methods of use thereof

#676
20240209364
2024-06-27

COMPOUNDS AND METHODS FOR MODULATING PLP1

#677
20240209362
2024-06-27

Linear DNA with Enhanced Resistance Against Exonucleases

#678
20240207440
2024-06-27

PHARMACEUTICAL COMPOSITION CONTAINING CELL-DERIVED NATURAL OR ARTIFICIAL NANOVESICLES LOADED WITH ANTISENSE OLIGONUCLEOTIDE-BASED DRUG

#679
20240200081
2024-06-20

NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE

#680
20240200075
2024-06-20

ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#681
20240200072
2024-06-20

Allogeneic Cartilage Regeneration

#682
20240200071
2024-06-20

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES

#683
20240200067
2024-06-20

Compositions for Modulating C9ORF72 Expression

#684
20240200064
2024-06-20

GENE THERAPY FOR INFLAMMATORY CONDITIONS

#685
20240200063
2024-06-20

MICROGLIAL GENE SILENCING USING DOUBLE-STRANDED SIRNA

#686
20240200061
2024-06-20

TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES

#687
20240200060
2024-06-20

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE

#688
20240197901
2024-06-20

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

#689
20240191254
2024-06-13

TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE

#690
20240191242
2024-06-13

TRANSGLUTAMINASE-MEDIATED CONJUGATION

#691
20240191240
2024-06-13

DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES

#692
20240191236
2024-06-13

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#693
20240191234
2024-06-13

Tuning cascade assay kinetics via molecular design

#694
20240191233
2024-06-13

COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION

#695
20240191232
2024-06-13

COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION

#696
20240191231
2024-06-13

SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES

#697
20240191229
2024-06-13

RNA SILENCING AGENTS AND METHODS OF USE

#698
20240191197
2024-06-13

MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

#699
20240189435
2024-06-13

NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF

#700
20240189339
2024-06-13

MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes

#701
20240182905
2024-06-06

TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#702
20240182904
2024-06-06

OLIGONUCLEOTIDES TARGETING S6K1

#703
20240182903
2024-06-06

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

#704
20240182902
2024-06-06

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#705
20240182901
2024-06-06

METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA

#706
20240182900
2024-06-06

MICRORNA BLOCKADE FOR THE TREATMENT OF DISEASE

#707
20240182898
2024-06-06

ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION

#708
20240182892
2024-06-06

DOUBLE-STRANDED SIRNA HAVING PATTERNED CHEMICAL MODIFICATIONS

#709
20240182890
2024-06-06

COMPOSITIONS AND METHODS FOR SITE-SPECIFIC MODIFICATION

#710
20240182889
2024-06-06

MICRORNA-27B INHIBITORS

#711
20240182561
2024-06-06

CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE

#712
20240175034
2024-05-30

FN3 DOMAIN-SIRNA CONJUGATES AND USES THEREOF

#713
20240175032
2024-05-30

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9

#714
20240175031
2024-05-30

TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

#715
20240175030
2024-05-30

ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#716
20240175026
2024-05-30

SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF

#717
20240175024
2024-05-30

DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES

#718
20240175023
2024-05-30

GalNAc compositions for improving siRNA bioavailability

#719
20240175021
2024-05-30

METHODS FOR MODULATING FMR1 EXPRESSION

#720
20240175018
2024-05-30

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF

#721
20240175017
2024-05-30

COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#722
20240175016
2024-05-30

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF

#723
20240167090
2024-05-23

FLAP PROBE AND USE THEREOF

#724
20240167032
2024-05-23

Methods for Treatment of Alport Syndrome

#725
20240167031
2024-05-23

NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM

#726
20240167029
2024-05-23

MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING

#727
20240158796
2024-05-16

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#728
20240158791
2024-05-16

METHOD OF TREATING FATTY LIVER DISEASE

#729
20240150764
2024-05-09

THERAPEUTIC SPLICE-SWITCHING OLIGONUCLEOTIDES FOR CANCER

#730
20240150761
2024-05-09

Modified Guide RNAs Comprising an Internal Linker for Gene Editing

#731
20240150757
2024-05-09

ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1

#732
20240150756
2024-05-09

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#733
20240150391
2024-05-09

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME

#734
20240141360
2024-05-02

MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA

#735
20240141355
2024-05-02

MODULATION OF GYS1 EXPRESSION

#736
20240141351
2024-05-02

ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE

#737
20240141348
2024-05-02

ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT

#738
20240141343
2024-05-02

Selective Antisense Compounds and Uses Thereof

#739
20240141340
2024-05-02

ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES

#740
20240141339
2024-05-02

Oligonucleotide Comprising Inosine for Treating DMD

#741
20240141336
2024-05-02

TARGETED RNA EDITING

#742
20240132895
2024-04-25

GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#743
20240132894
2024-04-25

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF

#744
20240132890
2024-04-25

NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION

#745
20240132889
2024-04-25

COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA

#746
20240132886
2024-04-25

COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#747
20240132885
2024-04-25

MODULATION OF TRANSTHYRETIN EXPRESSION

#748
20240132610
2024-04-25

Compositions and methods of treating facioscapulohumeral muscular dystrophy

#749
20240124882
2024-04-18

PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#750
20240124879
2024-04-18

RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF

#751
20240124600
2024-04-18

Compositions and methods of treating facioscapulohumeral muscular dystrophy

#752
20240122989
2024-04-18

METHODS AND COMPOSITIONS FOR PRODUCTION OF GENETICALLY MODIFIED PRIMARY CELLS

#753
20240117356
2024-04-11

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY

#754
20240117351
2024-04-11

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM

#755
20240117349
2024-04-11

iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)

#756
20240117348
2024-04-11

COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#757
20240117347
2024-04-11

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#758
20240117346
2024-04-11

MODIFIED HETERO NUCLEIC ACIDS

#759
20240117344
2024-04-11

METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF

#760
20240116973
2024-04-11

MODIFIED OLIGONUCLEOTIDES

#761
20240110190
2024-04-04

COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) AND OTHER DISORDERS

#762
20240110180
2024-04-04

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES

#763
20240110176
2024-04-04

PHOSPHOROTHIOATE NUCLEIC ACID CONJUGATES INCLUDING DNA EDITING ENZYMES

#764
20240109931
2024-04-04

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF

#765
20240102020
2024-03-28

POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF

#766
20240102018
2024-03-28

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#767
20240102017
2024-03-28

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#768
20240102014
2024-03-28

Tuning cascade assay kinetics via molecular design

#769
20240102012
2024-03-28

Compounds and methods for modulating SCN2A

#770
20240102011
2024-03-28

OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES

#771
20240102008
2024-03-28

CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF

#772
20240100132
2024-03-28

MODULATION OF AAV-BASED GENE EXPRESSION

#773
20240100080
2024-03-28

METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS

#774
20240093242
2024-03-21

GENE CORRECTION FOR SCID-X1 IN LONG-TERM HEMATOPOIETIC STEM CELLS

#775
20240093227
2024-03-21

STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED

#776
20240093201
2024-03-21

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#777
20240093199
2024-03-21

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE

#778
20240093192
2024-03-21

ANTISENSE OLIGONUCLEOTIDES INCREASING FOXG1 EXPRESSION

#779
20240093188
2024-03-21

RNAi AGENT TARGETING MYD88 AND USE THEREOF

#780
20240085402
2024-03-14

OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION

#781
20240084331
2024-03-14

Methods and Systems for Guide RNA Design and Use

#782
20240084301
2024-03-14

RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION

#783
20240084297
2024-03-14

CONJUGATED OLIGONUCLEOTIDES

#784
20240084296
2024-03-14

SINGLE-STRANDED OLIGONUCLEOTIDE

#785
20240084044
2024-03-14

Heteromultivalent Nucleic Acid Scaffolds and Uses Thereof

#786
20240082291
2024-03-14

COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION

#787
20240076676
2024-03-07

MODULATORS OF PNPLA3 EXPRESSION

#788
20240076675
2024-03-07

MODULATORS OF PNPLA3 EXPRESSION

#789
20240076673
2024-03-07

Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expression

#790
20240076659
2024-03-07

Linear DNA With Enhanced Resistance Against Exonucleases and Methods for the Production Thereof

#791
20240067974
2024-02-29

METHOD OF ALLELE SPECIFIC SILENCING FOR THE TREATMENT OF AUTOSOMAL DOMINANT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

#792
20240067971
2024-02-29

Target Ligand

#793
20240067969
2024-02-29

Compositions, systems, and methods for regulation of hepatitis B virus through targeted gene repression

#794
20240067968
2024-02-29

Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression

#795
20240067967
2024-02-29

OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS

#796
20240067964
2024-02-29

METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION

#797
20240067963
2024-02-29

COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISEASES

#798
20240067962
2024-02-29

Compounds and methods for modulating ATXN1

#799
20240066139
2024-02-29

Muscle targeting complexes and uses thereof for treating dystrophinopathies

#800
20240060068
2024-02-22

POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS

#801
20240059784
2024-02-22

TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES

#802
20240058370
2024-02-22

ANTISENSE COMPOUNDS

#803
20240052351
2024-02-15

ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR THE TREATMENT OF PAIN

#804
20240052350
2024-02-15

OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS

#805
20240052348
2024-02-15

DOUBLE STRANDED RNA TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF

#806
20240052345
2024-02-15

PHARMACEUTICAL COMPOSITION

#807
20240052344
2024-02-15

OLIGONUCLEOTIDES FOR PMS1 MODULATION

#808
20240043847
2024-02-08

NEW THERAPY

#809
20240043840
2024-02-08

CHEMICALLY MODIFIED CRISPR-CAS13 GUIDE RNAS

#810
20240043836
2024-02-08

COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

#811
20240042019
2024-02-08

OPTIMIZED TLR7 LIGANDS AND USES THEREOF

#812
20240035032
2024-02-01

Oligomers and oligomer conjugates

#813
20240033378
2024-02-01

ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES

#814
20240026425
2024-01-25

Compositions of matter for detection assays

#815
20240026364
2024-01-25

COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION

#816
20240026360
2024-01-25

OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION

#817
20240026358
2024-01-25

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#818
20240026353
2024-01-25

COMPOUNDS AND METHODS FOR MODULATING SCN2A

#819
20240018522
2024-01-18

OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING

#820
20240018519
2024-01-18

Stabilized saRNA Compositions and Methods of Use

#821
20240018518
2024-01-18

Tuning cascade assay kinetics via molecular design

#822
20240011032
2024-01-11

SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES

#823
20240011029
2024-01-11

MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES

#824
20240002858
2024-01-04

Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression

#825
20240002857
2024-01-04

DOUBLE STRANDED RNA TARGETING 17-BETA HYDROXYSTEROIDDEHYDROGENASE 13 (HSD17B13) AND METHODS OF USE THEREOF

#826
20240002853
2024-01-04

NUCLEIC ACID DUPLEXES

#827
20240002852
2024-01-04

COMPOUNDS FOR MODULATING CHMP7

#828
20240002851
2024-01-04

LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

#829
20240002849
2024-01-04

TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY

#830
20240002843
2024-01-04

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

#831
20240000824
2024-01-04

OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES

#832
20230416756
2023-12-28

MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION

#833
20230416752
2023-12-28

CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2

#834
20230416743
2023-12-28

COMPOSITIONS AND METHODS FOR INHIBITING SNCA EXPRESSION

#835
20230416742
2023-12-28

COMPOSITIONS AND METHODS FOR INHIBITING MAPT EXPRESSION

#836
20230416736
2023-12-28

MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#837
20230416735
2023-12-28

OLIGONUCLEOTIDES FOR ATN1 MODULATION

#838
20230416734
2023-12-28

UMLILO ANTISENSE TRANSCRIPTION INHIBITORS

#839
20230416733
2023-12-28

GUIDE RNA WITH CHEMICAL MODIFICATIONS

#840
20230414755
2023-12-28

METHODS AND COMPOSITIONS RELATING TO GENETICALLY ENGINEERED CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS

#841
20230407312
2023-12-21

METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION

#842
20230407311
2023-12-21

NUCLEIC ACIDS CONTAINING ABASIC NUCLEOTIDES

#843
20230407307
2023-12-21

MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS

#844
20230407302
2023-12-21

NOVEL EFFICACIOUS MICRORNA-30C ANALOGS REDUCE APOLIPOPROTEIN B SECRETION IN HUMAN LIVER CELLS

#845
20230407299
2023-12-21

TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS

#846
20230407295
2023-12-21

PROTECTING OLIGONUCLEOTIDES FOR CRISPR GUIDE RNA

#847
20230399682
2023-12-14

Compositions of matter for detection assays

#848
20230399659
2023-12-14

EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES

#849
20230399645
2023-12-14

OPTIMIZED SIRNA SCAFFOLDS

#850
20230399643
2023-12-14

COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME

#851
20230398231
2023-12-14

COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY

#852
20230398219
2023-12-14

COMPOSITIONS AND METHODS FOR CD38 MODIFICATION

#853
20230392156
2023-12-07

G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#854
20230392152
2023-12-07

Huntingtin (HTT) iRNA agent compositions and methods of use thereof

#855
20230392146
2023-12-07

OLIGONUCLEOTIDES FOR APP MODULATION

#856
20230383296
2023-11-30

MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF

#857
20230383294
2023-11-30

NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3

#858
20230383292
2023-11-30

TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY

#859
20230383277
2023-11-30

COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A

#860
20230374522
2023-11-23

COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITY

#861
20230374519
2023-11-23

COMPOUNDS AND METHODS FOR MODULATING PMP22

#862
20230374505
2023-11-23

Human XIST Antisense Oligonucleotides for X Reactivation Therapy

#863
20230374503
2023-11-23

COMBINATION

#864
20230365970
2023-11-16

Modified short interfering nucleic acid (siNA) molecules and uses thereof

#865
20230365965
2023-11-16

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#866
20230364233
2023-11-16

COMPOSITIONS AND METHODS FOR CD6 MODIFICATION

#867
20230357798
2023-11-09

GENE CORRECTION FOR X-CGD IN HEMATOPOIETIC STEM AND PROGENITOR CELLS

#868
20230357779
2023-11-09

COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION

#869
20230357776
2023-11-09

COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION

#870
20230357774
2023-11-09

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES

#871
20230357773
2023-11-09

OLIGONUCLEOTIDE TREATMENT OF HEPATITIS B PATIENTS

#872
20230355775
2023-11-09

Nucleic acid, composition and conjugate containing same, preparation method, and use thereof

#873
20230355651
2023-11-09

RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION

#874
20230348909
2023-11-02

DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES

#875
20230348904
2023-11-02

SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS

#876
20230348903
2023-11-02

OLIGONUCLEOTIDES

#877
20230340573
2023-10-26

Compositions of matter for detection assays

#878
20230340490
2023-10-26

COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION

#879
20230340487
2023-10-26

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME

#880
20230340485
2023-10-26

ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#881
20230340482
2023-10-26

MAPT RNA interference agents

#882
20230340480
2023-10-26

METHODS FOR INTRACELLULAR DELIVERY AND ENHANCED GENE TARGETING

#883
20230340479
2023-10-26

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

#884
20230340468
2023-10-26

METHODS FOR USING GUIDE RNAS WITH CHEMICAL MODIFICATIONS

#885
20230340464
2023-10-26

RNA-editing oligonucleotides and uses thereof

#886
20230340435
2023-10-26

Base editing of ANGPTL3 and methods of using same for treatment of disease

#887
20230332153
2023-10-19

Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof

#888
20230332147
2023-10-19

IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER

#889
20230332143
2023-10-19

RNA-editing oligonucleotides and uses thereof

#890
20230331837
2023-10-19

OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION

#891
20230330128
2023-10-19

OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES

#892
20230323421
2023-10-12

OLIGONUCLEOTIDES TARGETING XBP1

#893
20230323368
2023-10-12

NOVEL TLR9 AGONISTS

#894
20230323362
2023-10-12

COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME

#895
20230323357
2023-10-12

TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#896
20230323355
2023-10-12

ANTIVIRAL SILENCING RNA MOLECULES, CHEMICALLY MODIFIED ANTIVIRAL SILENCING RNA MOLECULES WITH ENHANCED CELL PENETRATING ABILITIES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF FOR TREATMENT OF VIRAL INFECTIONS

#897
20230323351
2023-10-12

Compositions for modulating tau expression

#898
20230323350
2023-10-12

RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)

#899
20230323345
2023-10-12

UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES

#900
20230321255
2023-10-12

Modulators of PCSK9 Expression